DrugPatentWatch Database Preview
REPAGLINIDE Drug Profile
» See Plans and Pricing
When do Repaglinide patents expire, and when can generic versions of Repaglinide launch?
Repaglinide is a drug marketed by Actavis Totowa, Aurobindo Pharma Ltd, Boscogen, Casi Pharms Inc, Mylan, Paddock Labs Llc, Sun Pharm Inds Inc, and Lupin Ltd. and is included in eight NDAs.
The generic ingredient in REPAGLINIDE is metformin hydrochloride; repaglinide. There are forty-nine drug master file entries for this compound. Additional details are available on the metformin hydrochloride; repaglinide profile page.
Summary for REPAGLINIDE


Recent Clinical Trials for REPAGLINIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Texas Diabetes Institute | Phase 4 |
Kuwait University | Phase 4 |
Dasman Diabetes Institute | Phase 4 |
Pharmacology for REPAGLINIDE
Drug Class | Glinide |
Mechanism of Action | Potassium Channel Antagonists |
Paragraph IV (Patent) Challenges for REPAGLINIDE
Tradename | Dosage | Ingredient | NDA | Submissiondate |
---|---|---|---|---|
PRANDIN | TABLET;ORAL | repaglinide | 020741 | 2005-02-10 |
US Patents and Regulatory Information for REPAGLINIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Actavis Totowa | REPAGLINIDE | repaglinide | TABLET;ORAL | 090008-001 | Jan 22, 2014 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
Paddock Labs Llc | REPAGLINIDE | repaglinide | TABLET;ORAL | 201189-003 | Jan 22, 2014 | AB | RX | No | No | Start Trial | Start Trial | Start Trial | |||
Boscogen | REPAGLINIDE | repaglinide | TABLET;ORAL | 091517-001 | Apr 24, 2015 | AB | RX | No | No | Start Trial | Start Trial | Start Trial | |||
Aurobindo Pharma Ltd | REPAGLINIDE | repaglinide | TABLET;ORAL | 203820-001 | Jan 22, 2014 | AB | RX | No | No | Start Trial | Start Trial | Start Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |